Snapshot from Sep 18, 2026 at 07:00 UTC. For live data and tracking: View Live
Business strategic investment

Medtronic invests in Pi-Cardia for TAVR

Analysis based on 9 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026

Sentiment
60
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The investment strengthens Medtronic's structural heart portfolio and positions it to capture growth in the complex TAVR market, likely boosting investor confidence and supporting its stock price. Pi-Cardia Ltd. gains financial backing and global distribution through Medtronic, accelerating adoption of its ShortCut device and enhancing its valuation.

Medical Devices Healthcare Technology

Medtronic plc announced a strategic investment in Pi-Cardia Ltd. Ltd., a privately held medical device company specializing in leaflet modification technologies for structural heart disease. The investment, up to $80 million, includes an option for Medtronic to acquire Pi-Cardia Ltd. upon achieving predefined milestones, with an estimated upfront acquisition price of up to $210 million plus potential earn-out payments. Medtronic is expected to become the exclusive global commercial distributor of Pi-Cardia Ltd.'s ShortCut device in 2027, expanding access across the United States, Europe, Japan, and other markets. ShortCut is the first United States — Food and Drug Administration-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction, demonstrating successful leaflet splitting in pivotal trials. The transaction is subject to regulatory approval and customary closing conditions. Medtronic's shares rose nearly 7% in pre-market trading following the announcement.

90 Medtronic invested in Pi-Cardia Pi-Cardia Ltd.
80 Medtronic became exclusive global distributor Pi-Cardia Ltd.
stock
Medtronic is the lead investor, committing up to $80 million and securing distribution and acquisition rights. The deal expands its structural heart portfolio and is viewed positively by the market, with shares up nearly 7%.
Importance 100.0 Sentiment 70.0
priv
Pi-Cardia Ltd. receives strategic investment and a path to acquisition, with its ShortCut device gaining global distribution through Medtronic. This validates its technology and accelerates commercial adoption.
Importance 100.0 Sentiment 80.0
govactor
The United States — Food and Drug Administration cleared ShortCut, which is central to the deal's value proposition, enabling its commercial use in the U.S.
Importance 40.0 Sentiment 50.0
per
As CEO of Pi-Cardia Ltd., Erez Golan is a key figure in the collaboration, expressing confidence in the partnership to advance leaflet modification technology.
Importance 40.0 Sentiment 60.0
cnt
The United States is a key market where Medtronic will distribute ShortCut, expanding patient access to the technology.
Importance 30.0 Sentiment 50.0
cnt
Israel is the home country of Pi-Cardia Ltd., and the investment highlights its medtech innovation ecosystem.
Importance 30.0 Sentiment 50.0
cnt
Japan is a key market where Medtronic will distribute ShortCut, expanding patient access to the technology.
Importance 30.0 Sentiment 50.0
loc
Europe is a key market where Medtronic will distribute ShortCut, expanding patient access to the technology.
Importance 30.0 Sentiment 50.0
per
Jorie Soskin, VP and GM of Medtronic's Structural Heart business, is a spokesperson for the investment, highlighting its strategic importance.
Importance 30.0 Sentiment 50.0
exch
Medtronic is listed on the New York Stock Exchange, and its stock price reacted positively to the announcement.
Importance 20.0 Sentiment 50.0
cnt
Republic of Ireland is the headquarters of Medtronic, and the announcement originates from there.
Importance 20.0 Sentiment 50.0
per
Co-founder of Pi-Cardia Ltd., Eyal Kolka is mentioned as a founder but has no direct role in the announced transaction.
Importance 20.0 Sentiment 50.0
priv
As an existing investor in Pi-Cardia Ltd., Sofinnova Partners stands to benefit from the increased valuation and potential acquisition.
Importance 20.0 Sentiment 50.0
priv
As an existing investor in Pi-Cardia Ltd., Sprig Equity stands to benefit from the increased valuation and potential acquisition.
Importance 20.0 Sentiment 50.0
per
As an investor in Pi-Cardia Ltd., Jacques Séguin stands to benefit from the increased valuation and potential acquisition.
Importance 20.0 Sentiment 50.0
Medtronic related ↔ United States
United States close ally ↔ Israel The United States considers Israel a vital strategic ally in the Middle East, providing substantial military and economi
United States ally ↔ Japan The United States considers Japan a cornerstone defense ally and a vital economic partner in the Indo-Pacific, with exte
Israel related ↔ Japan
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.